With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.
Structured well, shared decision making (SDM) tools offer an important, patient-centered solution for improving care quality and value. A new report released last week -- National Quality Partners Playbook: Shared Decision Making in Healthcare -- points the way forward. PhRMA is proud to support the development of the playbook, a culmination of the National Quality Forum’s work to convene leading stakeholders and patient advocates to advance best practices for shared decision making.
There is growing evidence that informed and empowered patients who are engaged in collaborative dialogue and decisions with their clinicians have the potential to drive better health outcomes, improve care quality and make our health care system more efficient. A recent report released by Avalere showed that:
- Early evidence suggests that SDM can improve key measures in health care quality that matter to patients and could drive more appropriate health care utilization
- SDM has the potential to play a critical role in the success of value-based payment models, but current evidence is only reflective of emerging stages of SDM practice and science
- More comprehensive, patient-centered approaches to assessing value can elevate SDM to the next level in supporting the move towards value-based health care system
The timely release of the playbook takes the crucial step of providing actionable, practical guidance for clinicians and health care organizations seeking to implement or strengthen shared decision making within their care settings. The playbook suggests:
- Engaging patients and health care providers in the development of SDM processes and tools
- Identifying relevant outcomes via a collaborative (co-designed) process that includes patients, clinicians, administrators and other stakeholders to ensure validity
- Selecting and implementing high-quality decision aids that meet the National Standards for the Certification of Patient Decision Aids to help patients make informed decisions
- Establishing accountability and incentives for engagement in SDM
The playbook is an important resource to spur meaningful change in the way care is provided, and overcome challenges to making SDM a common practice in health care. We hope that all stakeholders can leverage NQF’s detailed recommendations so our health care system can to implement strong shared decision-making processes and tools to support high value care.
Randy Burkholder
Randy Burkholder is a Vice President of Policy and Research at PhRMA. He has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.
Incomplete evaluations undermine patient access to transformational medicine
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
PhRMA presents research at ISPOR 2022
Innovative contracts continue to gain traction and improve quality of care
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
PhRMA Foundation recognizes inaugural Challenge Award recipients
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
The journey to better health care requires a holistic view
Medicare Monday: How Part B has evolved over the years
Modernizing FDA regulations to advance a value-driven health care system
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Improving care quality by engaging patients in shared decision making
Quality Metrics
Value-Driven Health Care
The Value Collaborative
Improving care quality by engaging patients in shared decision making
Improving care quality by engaging patients in shared decision making